内分泌性高血压筛查专家共识(2025版)  

Expert consensus on endocrine hypertension screening (2025 version)

作　　者：中国医师协会内分泌代谢科医师分会 中国内分泌性高血压协作组 李启富[2] 母义明[3] 胡金波[4] 杨淑敏[4] Chinese Endocrinologist Association;Chinese Endocrine Hypertension Collaborative Group;Li Qifu;Mu Yiming(不详;Department of Endocrinology,the First Affiliated Hospital of Chongqing Medical University,Sichuan-Chongqing Joint Key Laboratory of Metabolic Vascular Diseases,Chongqing 400016,China;Department of Endocrinology,the First Medical Center of Chinese PLA General Hospital,Beijing 100039)

机构地区：[1]不详 [2]重庆医科大学附属第一医院内分泌科、代谢性血管疾病川渝共建重点实验室,重庆400016 [3]解放军总医院第一医学中心内分泌科,北京100039 [4]重庆医科大学附属第一医院内分泌内科

出　　处：《中华内科杂志》2025年第4期288-301,共14页Chinese Journal of Internal Medicine

基　　金：国家重点研发计划“常见多发病防治研究”专项(2022YFC2505300)。

摘　　要：内分泌性高血压是常见的继发性高血压。该类患者常无特异性症状或体征,容易被漏诊、误诊。早筛早治可大幅提高该类疾病的诊治水平,并改善患者预后。中国医师协会内分泌代谢科医师分会及中国内分泌性高血压协作组基于临床证据和临床实践,就内分泌性高血压的筛查适宜人群、筛查方式、筛查结果解读等相关问题,经过多次讨论最终形成本共识。Endocrine hypertension is a common form of secondary hypertension.Affected patients often present without specific symptoms or signs,making the condition easy to overlook or misdiagnose.Early screening can greatly enhance the level of diagnosis while prompt treatment can improve the prognosis of patients.Based on clinical evidence and practice,the Chinese Endocrinologist Association and the Chinese Endocrine Hypertension Collaboration Group reached this consensus after extensive discussions on target populations,screening methods,interpretation of screening results,and other issues related to endocrine hypertension.

关 键 词：内分泌性高血压 筛查 专家共识 

分 类 号：R544.1[医药卫生—心血管疾病]